Therapeutic Exploratory (Phase II)

3,454 trials 1,368 recruiting

Filter these 3,454 trials by condition, country, sponsor and more.

Open in Search →

A randomized phase II trial of Mirvetuximab soravtansine (IMGN853), in folate receptor alpha (FRα) high recurrent ovarian cancer eligible fo… Ended

2024-516959-40-00 This trial evaluates the efficacy and safety of Mirvetu 2021-08-17
Evaluation of two maintenance therapies (OSE2101 alone or in combination with pembrolizumab) versus best supportive care in patient with pla… Ended

2024-516096-32-00 Platinum sensitive recurrent ovarian cancer 2021-08-05
DALY 2-EU Ended

2023-506270-13-00 Relapsed/refractory diffuse large B cell lymphoma (R-R 2021-07-27
Induction chemotherapy for locally advanced rectal cancer. Ended

2023-509758-74-00 Locally advanced rectal cancer 2021-07-21
Phase 2 Study of Axatilimab at 3 Different Doses in Patients with Chronic Graft Versus Host Disease. Ended

2024-512978-99-00 Chronic graft versus host disease (cGVHD) 2021-07-19
RECHALLENGE WITH PEGYLATED LIPOSOMAL DOXORUBICIN ADDED TO TRABECTEDIN IN RECURRENT OVARIAN CANCER: A MULTICENTER, PROSPECTIVE TRIAL.(REPRAB … Ended

2024-518847-40-00 recurrent ovarian cancer 2021-07-16
"Clinical Study of Inhaled GB002 for the Treatment of WHO Group 1 Pulmonary Arterial Hypertension (PAH)" Ended

2024-516754-22-00 Pulmonary Arterial Hypertension (PAH) 2021-07-14
A study to investigate anti-tumor activity and safety of trastuzumab deruxtecan in patients with solid tumors carrying specific HER2 mutatio… Ended

2024-516158-22-00 Treatment of unresectable and/or metastatic solid tumor 2021-07-06
Prospective, non randomized, Phase II study on MK-3475 in recurrent, platinum-resistant, CPS ≥1 positive ovarian, Fallopian tube and primary… Ended

2024-516629-30-00 Recurrent, platinum-resistant, CPS >1 positive ovarian, 2021-06-24
The REST (Replacing Steroids in the transplant ineligible) study. Ended

2023-510194-34-00 Multiple myeloma 2021-06-18
Phase 2 study of neoadjuvant immune checkpoint inhibitors in urothelial cancer (ABACUS-2) Ended

2024-510750-28-00 Tumours of the urothelial tract requiring surgery (T1 h 2021-06-18
A phase 2, open label study to evaluate safety and clinical activity of balstilimab in monotherapy in patients with advanced/metastatic non-… Ended

2024-517380-22-00 Advanced basal cell carcinoma not amenable to local the 2021-06-18
Chemotherapy-Free pCR-Guided Strategy with subcutaneous trastuzumabpertuzumab and T-DM1 in HER2-positive early breast cancer (PHERGAIN-2) Ended

2023-508738-32-00 Previously untreated and histologically confirmed HER2- 2021-06-16
Proof-of-concept study for SAR441344 (frexalimab) in relapsing multiple sclerosis. Ended

2024-513527-17-00 Multiple Sclerosis 2021-06-07
A Phase 2 Clinical Study to Assess the Safety and Efficacy of Deucravacitinib in Participants with Active DLE and/or SCLE Ended

2023-504161-22-00 Active Discoid and/or Subacute Cutaneous Lupus Erythema 2021-06-04
Daratumumab for first line treatment of transplant-ineligible myeloma patients followed by daratumumab re-treatment at first relapse (GMMG-D… Ended

2024-517761-17-00 Multiple Myeloma 2021-05-31
A Study of Relatlimab plus Nivolumab in Combination with Chemotherapy vs. Nivolumab in Combination with Chemotherapy in Participants with St… Ended

2023-508372-10-00 Non small Cell Lung cancer 2021-05-19
The aim of the study is to evaluate the efficacy of Ponatinib, either alone or in combination with chemotherapy, in inducing remission in pa… Ended

2024-516868-28-00 Ph+ Acute Lymphoblastic Leukemia 2021-05-04
Study to evaluate the efficacy and safety of MAS825 in patients with autoinflammatory diseases. Ended

2023-504419-34-00 Autoinflammatory diseases including NLRC4-Gain of Funct 2021-04-29
Study of efficacy and safety of LXH254 combinations in patients with previously treated unresectable or metastatic melanoma Ended

2024-511934-11-00 Previously treated unresectable or metastatic BRAFV600 2021-04-27
Study to evaluate safety and dosimetry of Lutathera in adolescent patients with GEP-NETs and PPGLs. Ended

2023-507444-37-00 somatostatin receptor positive gastroenteropancreatic n 2021-04-21
To test the safety, efficacy and tolerability of a drug called trametinib and determine the duration of treatment in children with histiocyt… Ended

2024-515896-37-00 histiocytic cell proliferation 2021-04-20
A research study to find out if the study treatment alpelisib (BYL719) is safe and can help others who have confirmed diagnosis of PIK3CA-re… Ended

2023-508530-34-00 PIK3CA-Related Overgrowth Spectrum (PROS) 2021-04-19
A study to compare how safe and well tolerated study drug Abelacimab (MAA868) is compared to another drug called Rivaroxaban in patients wit… Ended

2023-509066-38-00 Atrial Fibrillation 2021-04-16